Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Revascularisation in Patients with Cancer
Author(s): Miguel Nobre Menezes , Mamas A Mamas Added: 1 month ago

CV Disease in Special Populations

Intervention
Frailty in Cardio-oncology
Author(s): Ilaria Torre , Lorenzo Tinti , Ludovica Amore , et al Added: 3 weeks ago

CV Disease in Special Populations

Heart Failure
Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches
Author(s): Giulia Tamburrini , Celia de Cobos García , Teresa López Fernández Added: 5 months ago

CV Disease in Special Populations

Heart Failure
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 11 months ago

CV Disease in Special Populations

Heart Failure
ACC 25 Late-Breaking Discussion: The API-Cat Study
Author(s): Harriette Van Spall , Isabelle Mahé Added: 11 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the… View more

Anticoagulation

Vascular Disease and Surgery
ESC 23: The ONCO DVT Study
Author(s): Yugo Yamashita Added: 2 years ago
ESC 23 — In this concise interview, Dr Yugo Yamashita (Kyoto University Graduate School of Medicine, JP) reveals the findings of the ONCO DVT Study (NCT03895502). The ONCO DVT study (Takeshi Morimoto) aimed to determine the ideal duration of anticoagulation therapy with the direct oral anticoagulant (DOAC) edoxaban for the treatment of isolated distal deep vein thrombosis (IDDVT) in patients… View more

Anticoagulation

Vascular Disease and Surgery
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations
Dr Michael D Stubblefield is Medical Director for Cancer Rehabilitation at Kessler Institute for Rehabilitation, National Medical Director for Select Medical’s ReVital Cancer Rehabilitation Program and National Medical Director for Complex Medical Rehabilitation for Select Medical’s Inpatient Rehabilitation Hospital Division. He is President of the International Cancer Rehabilitation Foundation… View more
Teresa Taft Levitch is a strategic healthcare communicator, writer, and patient advocate whose work focuses on cancer rehabilitation, survivorship, and cardiovascular health. She has developed patient-centered content and campaigns for organisations including the CDC Foundation, AstraZeneca, Memorial Sloan Kettering Cancer Center, the American Heart Association, and the Cancer Survivorship &… View more
Frailty and Cardio-oncology
Author(s): Erkihun Amsalu , Tan Van Nguyen , Harry Klimis , et al Added: 3 months ago

CV Disease in Special Populations